FINWIRES · TerminalLIVE
FINWIRES

市場傳聞:亞馬遜計畫重啟真人秀節目《學徒》。

By

-- 根據《華爾街日報》週四援引知情人士報道,亞馬遜(AMZN)正在考慮重啟真人秀節目《學徒》(The Apprentice),目前正在討論邀請小唐納德·特朗普出演新一季。 報道稱,相關討論尚處於早期階段,亞馬遜尚未與川普家族接洽。據悉,該節目由唐納德·川普總統主持,曾在NBC電視台播出14季。 消息人士告訴《華爾街日報》,亞馬遜在2025年3月在Prime Video上發布了原版節目的部分劇集,在川普贏得2024年美國總統大選後,亞馬遜急於重啟該節目。 亞馬遜尚未回覆的置評請求。 (市場閒談新聞來自與全球市場專業人士的對話。我們認為這些資訊來自可靠來源,但可能包含傳聞和猜測。我們不保證其準確性。)

Price: $261.90, Change: $-1.14, Percent Change: -0.43%

Related Articles

Mining & Metals

Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share

$AEM.TO
Treasury

TD Bank Group Issues 150 Million Swiss francs Green Bond

Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.

$TD$TD.TO
Research

Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.

$AMGN